Form 8-K GALECTIN THERAPEUTICS For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Galectin Therapeutics (GALT) Misses Q3 EPS by 6c
November 9, 2015 8:04 AM ESTGalectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.26), $0.06 worse than the analyst estimate of ($0.20).
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
... More


